In 2024, Oncode Institute demonstrated how fundamental scientific research can have a direct impact on both patients and society. The urgency remains high, but this year we once again proved that our approach works. By combining scientific excellence with proactive valorisation and strong collaboration, we took tangible steps towards real impact for patients and for society as a whole.
Tangible results with real progress for Patients
The secret behind this success? A unique approach that brings together leading researchers, encourages cross-disciplinary collaboration, and actively facilitates valorisation. This resulted in concrete outcomes from the launch of spin-offs such as Laigo Bio and Cell Control, to clinical studies emerging from fundamental research.
For example, the work of Jacco van Rheenen on the influence of the menstrual cycle on the effectiveness of chemotherapy in mice is now forming the basis for a clinical trial. Impressive progress was also made by Oncode Investigator Jeroen de Ridder, whose Sturgeon technology developed for brain surgery is proving to be of great value to patients. In 2024, this technology was already applied in children with brain tumours and is now being further developed for use in adults.
Jan Paul Medema, Scientific Director of Oncode Institute
“In 2024, we demonstrated that groundbreaking science and societal impact can go hand in hand,” says Jan Paul Medema, Scientific Director of Oncode Institute. “By investing in new knowledge about cancer and working closely with both the clinic and industry, we are building a future in which cancer becomes less disruptive to people’s lives and to society as a whole.”
Outsmarting Cancer
Oncode Institute will continue this mission in 2025 with new talent, strengthened international collaborations, and an ecosystem that transforms science into both health impact and economic value. In doing so, Oncode continues to demonstrate that investing in fundamental cancer research is essential to gaining a deeper understanding of the disease.